NASDAQ:OASM

Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.02
$0.02
50-Day Range
$1.30
$1.62
52-Week Range
$0.94
$5.70
Volume
N/A
Average Volume
98,414 shs
Market Capitalization
$1.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

OASM Stock News Headlines

Lipigon Pharmaceuticals AB LPGO
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Resurs Holding AB (publ) (RESURS.ST)
QuiaPEG Pharmaceuticals Holding AB QUIA
Newbury Pharmaceuticals AB (NEWBRY)
Lipigon Pharmaceuticals AB (LPGO)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Speqta publ AB (SPEQT)
PRXXF Paradox Interactive AB (publ)
Orexo appoints Fredrik Järrsten as new CFO
Notice of extra general meeting in Terranet AB
Fancy Wood Industries PCL (FANCY)
See More Headlines
Receive OASM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OASM
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-18,950,000.00
Net Margins
-8,633.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$220,000.00
Book Value
$0.63 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.50 million
Optionable
Not Optionable
Beta
0.96
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • François R. Martelet
    Chief Executive Officer
  • Fredrik Järrsten
    Chief Financial Officer
  • Mikael Asp
    Chief Technology Officer
  • Nigel Goodman
    Director-Clinical Operations
  • Carina Eklöw
    Director-Global Medical Affairs

OASM Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Novavax (NVAX) and OpGen (OPGN).

This page (NASDAQ:OASM) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners